Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments

Full text
Author(s):
Ramos de Mattos, Bruno Rafael [1] ; Gracindo Garcia, Maellin Pereira [1, 2] ; Nogueira, Julia Bier [1] ; Paiatto, Lisiery Negrini [1] ; Albuquerque, Cassia Galdino [1] ; Souza, Caique Lopes [1] ; Romani Fernandes, Luis Gustavo [2, 3] ; da Silva Cunha Tamashiro, Wirla Maria [1] ; Simioni, Patricia Ucelli [1, 2, 4]
Total Authors: 9
Affiliation:
[1] Univ Campinas Unicamp, Inst Biol, Dept Genet Evolut & Bioagents, BR-13083970 Campinas, SP - Brazil
[2] Fac Americana, Dept Biomed Sci, BR-13477360 Americana, SP - Brazil
[3] Univ Estadual Campinas, Sch Med, BR-13083887 Campinas, SP - Brazil
[4] Univ Estadual Paulista UNESP, Inst Biosci, Dept Biochem & Microbiol, BR-13506900 Rio Claro, SP - Brazil
Total Affiliations: 4
Document type: Review article
Source: Mediators of Inflammation; 2015.
Web of Science Citations: 47
Abstract

Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance of the intestinal microbiota. Crohn's disease (CD) and ulcerative colitis (UC) are the most widely known types of IBD and have been the focus of attention due to their increasing incidence. Recent studies have pointed out genes associated with IBD susceptibility that, together with environment factors, may contribute to the outcome of the disease. In ulcerative colitis, there are several therapies available, depending on the stage of the disease. Aminosalicylates, corticosteroids, and cyclosporine are used to treat mild, moderate, and severe disease, respectively. In Crohn's disease, drug choices are dependent on both location and behavior of the disease. Nowadays, advances in treatments for IBD have included biological therapies, based mainly on monoclonal antibodies or fusion proteins, such as anti-TNF drugs. Notwithstanding the high cost involved, these biological therapies show a high index of remission, enabling a significant reduction in cases of surgery and hospitalization. Furthermore, migration inhibitors and new cytokine blockers are also a promising alternative for treating patients with IBD. In this review, an analysis of literature data on biological treatments for IBD is approached, with the main focus on therapies based on emerging recombinant biomolecules. (AU)

FAPESP's process: 13/20258-2 - Effects of oral tolerance and tolerogenic dendritic cell administration on the immune response in experimental colitis
Grantee:Patricia Ucelli Simioni
Support type: Regular Research Grants